Katherine Lewis, MD
Pediatric Endocrinology · Greenville, SCNPI 1871507046
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 95 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 11.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $594 and has fallen 67.5% since, to $193 in 2025.
Across 95 payments — averaging $18.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dexcom, Inc.$193
- Lilly USA, LLC$171
- Insulet Corporation$146
- Tandem Diabetes Care, Inc.$115
- Abbott$110
- Novo Nordisk$107
- plus $914 from 21 others
What the payments were for
- Food & beverage$1,756100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dexcom, Inc. | 20 | $193 |
| Lilly USA, LLC | 8 | $171 |
| Insulet Corporation | 6 | $146 |
| Tandem Diabetes Care, Inc. | 4 | $115 |
| Abbott | 5 | $110 |
| Novo Nordisk | 7 | $107 |
| Medtronic | 3 | $87 |
| AbbVie | 4 | $83 |
| Xeris Pharmaceuticals, Inc. | 4 | $82 |
| Ascendis Pharma Endocrinology Inc | 2 | $73 |
| Sanofi-aventis U.S. LLC | 4 | $66 |
| Novartis | 3 | $62 |
| Radius Health, Inc. | 2 | $54 |
| Amgen | 3 | $52 |
| Corcept Therapeutics | 3 | $52 |
| Embecta Corp. | 2 | $44 |
| Boehringer Ingelheim | 3 | $43 |
| Lifescan, Inc. | 2 | $34 |
| Antares Pharma, Inc. | 2 | $32 |
| Intuity Medical Inc | 1 | $24 |
| Ascensia Diabetes Care US Inc. | 1 | $24 |
| Sequel Med Tech, LLC | 1 | $20 |
| Cequr Corporation | 1 | $17 |
| Pfizer | 1 | $17 |
| Boston Scientific | 1 | $17 |
| Amneal Pharmaceuticals LLC | 1 | $16 |
| Arbor Pharmaceuticals, Inc. | 1 | $16 |
How this compares
Too few pediatric endocrinology providers in South Carolinato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 60 | $86,805 |
| TrulicityDulaglutide | 38 | $50,797 |
| MounjaroTirzepatide | 26 | $45,385 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 12 | $32,880 |
| JardianceEmpagliflozin | 21 | $27,956 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $22,771 |
| RybelsusSemaglutide | 13 | $22,225 |
| Tresiba Flextouch U-100Insulin Degludec | 53 | $20,038 |
| Novolog FlexpenInsulin Aspart | 31 | $14,376 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 23 | $10,532 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 22 | $9,392 |
| Humalog Kwikpen U-100Insulin Lispro | 22 | $9,359 |
| Gvoke Hypopen 2-PackGlucagon | 16 | $9,350 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 58 | $8,430 |
| NovologInsulin Aspart | 22 | $6,951 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $107 | $115,98195 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $171 | $100,70588 claims |
| Boehringer IngelheimJardiance | $43 | $27,95621 claims |
| AbbVieSynthroid | $83 | $2,25846 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $16 | $1,867224 claims |
| PfizerLevoxyl | $17 | $1,19118 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few pediatric endocrinology providers in South Carolinaon file to place this against a meaningful peer group, so we don't.
Other pediatric endocrinology in Greenville
- Elaine AppersonGreenville$46K
- Ryan DyessGreenville$2K
- Melissa GargantaGreenville$925
- James AmrheinGreenville$574
- Mary RoperGreenville$113
- Alison LunsfordColumbia$13K
- Tarina MendesSeneca$5K
- Deidre McSweeny-TysonFlorence$3K
- Lisa KnightColumbia$3K
- Whitney BrownColumbia$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.